Investors Sell Alexion Pharmaceuticals, Inc. (ALXN) on Strength (ALXN)

Traders sold shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on strength during trading hours on Wednesday. $48.35 million flowed into the stock on the tick-up and $97.71 million flowed out of the stock on the tick-down, for a money net flow of $49.36 million out of the stock. Of all equities tracked, Alexion Pharmaceuticals had the 0th highest net out-flow for the day. Alexion Pharmaceuticals traded up $0.36 for the day and closed at $110.34

Several research firms have recently commented on ALXN. Royal Bank Of Canada began coverage on Alexion Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $161.00 price objective for the company. J P Morgan Chase & Co upgraded Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $163.00 to $175.00 in a report on Tuesday, September 5th. Deutsche Bank AG restated a “buy” rating and set a $158.00 price objective (up previously from $153.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. BMO Capital Markets restated an “outperform” rating and set a $173.00 price objective (up previously from $168.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $180.00 price objective (up previously from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $154.01.

The company has a market capitalization of $24,651.02, a P/E ratio of 22.56, a price-to-earnings-growth ratio of 1.20 and a beta of 1.22. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.32 by $0.12. The firm had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company’s revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.23 EPS. research analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current fiscal year.

In related news, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now directly owns 5,480 shares in the company, valued at approximately $799,038.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Julie O’neill sold 11,160 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total value of $1,562,400.00. Following the transaction, the executive vice president now owns 26,704 shares in the company, valued at $3,738,560. The disclosure for this sale can be found here. Insiders have sold a total of 16,490 shares of company stock worth $2,337,251 over the last quarter. Corporate insiders own 4.35% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rathbone Brothers plc lifted its holdings in Alexion Pharmaceuticals by 2.5% in the 2nd quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 50 shares during the period. Seven Bridges Advisors LLC lifted its stake in shares of Alexion Pharmaceuticals by 2.1% in the 2nd quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 53 shares during the period. Geneva Advisors LLC lifted its stake in shares of Alexion Pharmaceuticals by 0.7% in the 2nd quarter. Geneva Advisors LLC now owns 11,408 shares of the biopharmaceutical company’s stock valued at $1,388,000 after purchasing an additional 82 shares during the period. Grandfield & Dodd LLC lifted its stake in shares of Alexion Pharmaceuticals by 2.8% in the 2nd quarter. Grandfield & Dodd LLC now owns 3,360 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 90 shares during the period. Finally, Louisiana State Employees Retirement System lifted its stake in shares of Alexion Pharmaceuticals by 0.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 13,900 shares of the biopharmaceutical company’s stock valued at $1,691,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.

WARNING: “Investors Sell Alexion Pharmaceuticals, Inc. (ALXN) on Strength (ALXN)” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://ledgergazette.com/2017/11/17/investors-sell-alexion-pharmaceuticals-inc-alxn-on-strength-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply